ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,092Medicare Part D Prescriptions Filled, Including Refills

Rank: 656 out of 2888

$555K Total Retail Price of All Prescriptions

Rank: 716 out of 2888

624 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
18% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Texas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

14% of this provider’s 624 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

1% of this provider’s 8,315 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$61 was the average price of a prescription from this provider, compared to $67 among peers.

Prescriptions per Patient

15 is the average number of prescriptions (including refills) per patient, compared to an average of 19.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Texas
OMEPRAZOLE 361 330 1 7
ZOLPIDEM TARTRATE 323 266 2 17
SIMVASTATIN 279 259 3 2
HYDROCODONE-ACETAMINOPHEN 273 246 S3 4 4
LISINOPRIL 260 242 5 3
LEVOTHYROXINE SODIUM 250 232 6 1
AMLODIPINE BESYLATE 241 241 7 5
TRAMADOL HCL 154 150 8 16
GABAPENTIN 149 138 9 13
POTASSIUM CHLORIDE 149 145 9 14
SERTRALINE HCL 144 136 11 27
ATORVASTATIN CALCIUM 141 131 12 9
METFORMIN HCL 140 129 13 8
BISOPROLOL-HYDROCHLOROTHIAZIDE 129 125 14 193
MELOXICAM 128 112 15 31
CARVEDILOL 125 108 16 21
METOPROLOL TARTRATE 121 107 17 10
METOPROLOL SUCCINATE 116 98 18 11
TERAZOSIN HCL 111 111 19 152
TAMSULOSIN HCL 98 93 20 29
FLUTICASONE PROPIONATE 96 95 21 32
NAMENDA 93 93 22 34
FUROSEMIDE 88 77 23 6
WARFARIN SODIUM 84 81 24 22
PRAVASTATIN SODIUM 83 81 25 12
CLONIDINE HCL 79 78 26 39
GLIMEPIRIDE 77 74 27 36
LISINOPRIL-HYDROCHLOROTHIAZIDE 76 75 28 28
DIOVAN HCT 75 69 29 61
CITALOPRAM HBR 73 68 30 24
LOSARTAN POTASSIUM 70 69 31 18
PREDNISONE 70 65 31 42
NEXIUM 68 63 33 19
CIPROFLOXACIN HCL 67 62 34 47
ALLOPURINOL 66 64 35 37
ZETIA 65 65 36 81
RAMIPRIL 64 64 37 73
DIOVAN 63 61 38 35
BUPROPION XL 61 36 39 212
CELEBREX 59 59 40 89
LYRICA 59 53 40 69
AZITHROMYCIN 56 43 42 38
JANUVIA 56 52 42 48
LIPITOR 55 51 44 78
DONEPEZIL HCL 55 55 44 26
TRAZODONE HCL 54 45 46 43
SYNTHROID 53 53 47 52
ROPINIROLE HCL 53 46 47 115
SULFAMETHOXAZOLE-TRIMETHOPRIM 53 52 47 88
ETODOLAC 51 41 50 170
ADVAIR DISKUS 51 51 50 60
CRESTOR 50 50 52 20
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 12, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.